WishBone Medical confirmed a private label distribution agreement with Bone Solutions, Inc. (BSI) for worldwide rights within pediatric orthopedics to license and sell OsteoCrete.
OsteoCrete, a magnesium-based bone void filler, is designed to assist with bone repair and regeneration. It is the first device of its kind in the orthopedic market with 510(k) approval from the FDA, according to a release.
The device is an injectable, moldable solution designed to attach ligaments and tendons to bone, as well as bone to bone, with a composition that is three times stronger than cancellous bone.
Colleyville, Texas-based BSI reported more than 600 cases implanting OsteoCrete this year.
“For so many years, the orthopedics industry demonstrated a clear demand for osteogenic implants which mimic properties of the human bone,” BSI president and CEO Drew Diaz said in prepared remarks. Prior to OsteoCrete, calcium-based solutions contributed to bone healing, but with little mechanical support. Not only is OsteoCrete 100% resorbable – it offers excellent bone remodeling during the window of healing with uncompromised strength.”
“This product is the holy grail for pediatric orthopedics as the resorbable properties eliminate the need for secondary operations,” WishBone founder and CEO Nick Deeter added. “Kids already harbor a lot of anxieties around the idea of surgery. If we can save patients and their families the expense and worries of follow-up procedures, that alone is a big win.”
